Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marinus Pharmaceuticals, Inc.

http://marinuspharma.com/

Latest From Marinus Pharmaceuticals, Inc.

EMA Backs EU Approval For Ztalmy & Pylclari Roche Withdraws EU Filing For AMD Implant

Two new products, one for epilepsy and the other for prostate cancer, were recommended for EU approval during the latest monthly meeting of the European Medicines Agency’s human medicines committee, the CHMP.

Approvals Europe

EMA: Marinus Filing Up For An Opinion; Amylyx, GSK & Curium Due For Oral Explanations

The European Medicines Agency’s human medicines committee, the CHMP, is meeting this week to discuss the EU marketing applications for a number of products that have reached the late stages of the regulatory review cycle.

Europe Approvals

FDA’s Novel Approvals Again Led By Oncology And Neurology, But Dermatology Also Shone In 2022

Pink Sheet infographic breaks down the trends and surprises in 2022 approvals. Cancer therapies and non-malignant hematology exceeded the average use of expedited review programs but were weighted to orphan diseases, while dermatology saw first-in-class approvals for big markets.

Pink Sheet Perspectives Approvals

Generics And Biosimilars Industry Reshaped By Transformations

The latest Generics Bulletin Top 50 ranking of global generics and biosimilars companies sees a new name in the top five amid transformations for some of the leading off-patent players. Meanwhile, a number of mid-level firms shift position and newcomers climb into the bottom of the table.

Outlook 2023 Generic Drugs
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Nanotechnology, Chips, etc.
UsernamePublicRestriction

Register